ObjectiveTo assess the effect of Xuezhikang 1.2 g/d after 4 weeks' treatment on primary hyperlipidemia patients' lipid contents including total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C) by literature analysis. MethodsA literature research was carried out in CNKI, Wanfang and Weipu full-text database to collect articles published from January 1st, 1994 to August 30 th, 2014, concerning the self-controlled trials on the lipid regulating effects of Xuezhikang 1.2 g/d for 4 weeks in primary hyperlipidemia patients. Statistical analysis was performed with Review Manager 5.2. ResultsFifty-five independent trials were included in this review. All of the independent studies showed no homogeneity (P<0.01, I2>70%), and had publication bias. The contents of TC, TG, and LDL-C after a 4-week treatment with 1.2 g/d Xuezhikang were significantly lower than those before treatment [WMD=1.14 mmol/L, 95%CI (1.02, 1.25) mmol/L, P<0.000 01; WMD=0.72 mmol/L, 95%CI (0.59, 0.85) mmol/L, P<0.000 01; WMD=0.87 mmol/L, 95%CI (0.74, 1.00) mmol/L, P<0.000 01] and the contents of HDL-C was significantly higher than that before treatment [WMD=-0.16 mmol/L, 95%CI (-0.26, -0.12) mmol/L, P<0.000 01]. ConclusionXuezhikang can reduce the primary hyperlipidemia patients' TC, TG and LDL-C, and increase HDL-C after 4 weeks' treatment.
目的:探讨普罗布考对动脉粥样硬化性脑梗死并高脂血症患者血脂及预后的影响。方法:将87例脑梗死并高脂血症患者随机分为两组,治疗组44例,对照组43例,两组除按动脉粥样硬化性脑梗死常规治疗外,停用一切降脂药物。治疗组给予普罗布考500mg bid/d。疗程为6个月。随访一年观察两组患者治疗后血脂水平及脑血管事件发生情况。结果:治疗组患者治疗前、后总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白(LDL)、高密度脂蛋白(HDL)间差异均有显著性意义(Plt;0.05)。两组患者治疗后各项血脂指标间差异均有显著性意义(Plt;0.05)。随访一年,显示治疗组患者心脑血管事件14次,对照组19次(Plt;0.05)。结论:普罗布考降脂疗效可靠、副作用轻微,降低心脑血管事件发生。可作为动脉粥样硬化性脑梗死并高脂血症患者的一、二级预防药物。
In recent years, the incidence of hyperlipidemia acute pancreatitis (HLAP) has been increasing year by year, but its pathogenesis has not been completely clear. There are many clinical treatment methods for HLAP, such as lipid-lowering drugs, low molecular weight heparin, insulin, and plasma exchange. Actively reducing serum triglyceride is the core of treatment. Plasma exchange can quickly and effectively reduce the level of triglyceride, and its application in the treatment of HLAP is gradually increasing. This article reviews the recent advances in the pathogenesis, clinical characteristics, diagnosis, and treatment of HLAP, focusing on the mechanism, indications, timing, and disadvantages of plasma exchange therapy for HLAP.
ObjectiveTo investigate the therapeutic effect of B ultrasound-guided percutaneous catheter drainage combined with veno-venous hemofiltration at different time points and multi-site in treatment of hyperlipidemic severe acute pancreatitis (HL-SAP). MethodsThe clinical data of 34 patients with HL-SAP initially underwent B ultrasound-guided percutaneous catheter drainage combined with veno-venous hemofiltration at different time points and multi-site from January 2010 to June 2014 were retrospectively analyzed. According to the different of the onset to treatment time, 34 cases were divided into the≤24 h group and > 24 h group. The serum platelet activating factor (PAF) and triglyceride (TG) at the time of admission and after admission 1, 3, 5, 7, and 10 days were detected, and the hospitalization time, mortality, and the rate of conversion to open surgery were observed. ResultsThe levels of PAF and TG in the both groups tended to gradually decrease with different degrees, were significantly lower than that the before treatment (P < 0.05), and the decline of PAF and TG in≤24 h group were more significant than > 24 h group. The hospitalization time, mortality, and the rate of conversion to open surgery in the≤24 h group were significantly lower than those of the > 24 h group (P < 0.05). ConclusionThe early using of B ultrasound-guided percutaneous catheter drainage combined with veno-venous hemofiltration at different time points and multi-site would have a beneficial impact on the management of HL-SAP and complications.
目的:比较伴或不伴高脂血症的系统性红斑狼疮(SLE)患者的狼疮性肝损害的构成比例,了解高脂血症与狼疮性肝损害的相关性。方法:收集SLE患者100例,根据高脂血症和狼疮性肝损害的诊断标准,将患者分为高脂血症组,非高脂血症组和肝损害组,非肝损害组,收集其相关临床数据进行比较分析。结果:1高脂血症组发生肝损害的比例高于非高脂血症组(χ2=9.908,P=0.002);2血脂水平中甘油三酯与γGT(r=0366,P=0.000),碱性磷酸酶(r=0.241,P=0.018),强的松剂量(r=0.31,P=0.006),24h尿蛋白定量(r=0.273,P=0.007)相关;TC与24h尿蛋白定量(r=0.273,P=0.007)相关;HDL与γ谷氨酸转肽酶(r=0.233,P=0.022),碱性磷酸酶(r=0.265,P=0.009)相关;3-SLE活动组出现高脂血症的比例高于非活动组(χ2=6.986,P=0.008)。结论:长期的高脂血症可导致或加重SLE患者肝功能损害,高脂血症是狼疮性肝损害的危险因素之一。
目的 探讨成都市高脂血症患病率及合并心血管危险因素的现状及城乡差异。 方法 2010年3月－11月随机抽样选取城市和农村社区，采用问卷、体格检查和实验室检查共调查35～70岁人群2 032例，其中城市社区1 015例，农村社区1 017例。进一步调查其中高脂血症患者合并的主要心血管危险因素。 结果 ① 成都市城乡高脂血症患病率为23.53%（474/2 032）。城市高于农村，分别为27.88%（283/1 015）和18.78%（283/1 017）；② 城市高脂血症人群中合并高血压、糖尿病和冠心病均高于农村。高脂血症合并高血压人群最多，城乡分别是51.95%（147/283）和31.94%（61/191），其次是合并“糖尿病”和“冠心病”人群；③ 城市高脂血症患者合并高血压人群无论男女均高于农村，但城市男性合并糖尿病者高于农村，城市女性合并冠心病者高于农村；④ 城乡高脂血症患者在合并饮酒、脑卒中史、腹型肥胖和肥胖之间差异无统计学意义（P＜0.05）。 结论 高血压、糖尿病和冠心病是城市高脂血症患者干预的重点危险因素。其中城市男性的糖尿病和城市女性冠心病干预更为重要。
ObjectiveTo systematically review the efficacy and safety of electroacupuncture in animal hyperlipidemia models. MethodsDatabases such as CNKI, WanFang Data, VIP, CBM, PubMed, EMbase and The Cochrane Library (Issue 12, 2013) were searched for studies concerning the efficacy and safety of electroacupuncture in animal hyperlipidemia models up to December 2013. Two reviewers independently screened literature according to the inclusion and exclusion criteria, extracted data and assessed the methodological quality of included studies by using reformative CAMARADES List. Then, meta-analysis was performed by using RevMan 5.2 software. ResultsA total of 4 studies involving 89 rats were included. The average score of CAMARADES List was 4. The results of meta-analysis showed that:there were no significant differences between electroacupuncture group and medication group in reducing the levels of TC (MD=0.06, 95%CI -0.08 to 0.20, P=0.40), TG (MD=-0.01, 95%CI -0.08 to 0.06, P=0.74), LDL-C (MD=0.01, 95%CI -0.04 to 0.03, P=0.65) and increasing the level of HDL-C (MD=-0.00, 95%CI -0.09 to 0.08, P=0.93). ConclusionCurrent evidence shows that there are no differences between electroacupuncture and medication in reducing levels of TC, TG, LDL-C and increasing the level of HDL-C in hyperlipidaemia rats. But due to the limitation of sample size of included studies, more large-scale, high quality studies are needed.